Monoamine oxidase inhibition and CNS immunodeficiency infection.
HIV invades CNS subcortical areas, particularly the dopamine-rich basal ganglia and induces a subcortical dementia. Data suggest that the basal ganglia dysfunction plays a critical role in the neuropsychiatric manifestation of HIV infection. Therefore, therapeutic approaches for HIV dementia nowadays wish to include apart from the highly active antiretroviral therapy (HAART) also adjunctive medication. In this short article, we report briefly on neurotoxicity associated with the immunodeficiency virus and discuss the effects of selegiline, a monoamine oxidase inhibitor which enhances dopamine availability in CNS on immunodeficiency virus-induced neurological disease.
Koutsilieri
E
E
Clinical Neurochemistry, National Parkinson Foundation Center of Excellence Research Laboratory, Department of Psychiatry and Psychotherapy, Julius-Maximilians-University, Füchsleinstr 15, 97080 Würzburg, Germany. eleni.koutsilieri@mail.uni-wuerzburg.de
Scheller
C
C
ter Meulen
V
V
Riederer
P
P
D000818:Animals; D002494:Central Nervous System Infections / Q000139:chemically induced / Q000201:enzymology* / Q000473:pathology; D015658:HIV Infections / Q000139:chemically induced / Q000201:enzymology* / Q000473:pathology; D006801:Humans; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*
D008996:Monoamine Oxidase Inhibitors; D008995:Monoamine Oxidase